| Title: | Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors |
| Authors: | Hontani, Koji Browse this author |
| Tsuchikawa, Takahiro Browse this author →KAKEN DB |
| Hiwasa, Takaki Browse this author |
| Nakamura, Toru Browse this author →KAKEN DB |
| Ueno, Takashi Browse this author |
| Kushibiki, Toshihiro Browse this author |
| Takahashi, Mizuna Browse this author |
| Inoko, Kazuho Browse this author |
| Takano, Hironobu Browse this author |
| Takeuchi, Satoshi Browse this author |
| Dosaka-Akita, Hirotoshi Browse this author →KAKEN DB |
| Kuwatani, Masaki Browse this author →KAKEN DB |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Hatanaka, Yutaka Browse this author →KAKEN DB |
| Mitsuhashi, Tomoko Browse this author →KAKEN DB |
| Shimada, Hideaki Browse this author |
| Shichinohe, Toshiaki Browse this author →KAKEN DB |
| Hirano, Satoshi Browse this author →KAKEN DB |
| Keywords: | pancreatic neuroendocrine tumors |
| SEREX |
| biomarker |
| prognostic factor |
| EID3 |
| Issue Date: | 5-Dec-2017 |
| Publisher: | Impact Journals |
| Journal Title: | Oncotarget |
| Volume: | 8 |
| Issue: | 63 |
| Start Page: | 106206 |
| End Page: | 106221 |
| Publisher DOI: | 10.18632/oncotarget.22175 |
| Abstract: | Pancreatic neuroendocrine tumors (pNETs) are relatively rare heterogenous tumors, comprising only 1-2% of all pancreatic neoplasms. The majority of pNETs are non-functional tumors (NF-pNETs) that do not produce hormones, and as such, do not cause any hormone-related symptoms. As a result, these tumors are often diagnosed at an advanced stage because patients do not present with specific symptoms. Although tumor markers are used to help diagnosis and predict some types of cancers, chromogranin A, a widely used tumor marker of pNETs, has significant limitations. To identify novel NF-pNET-associated antigens, we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX) and identified five tumor antigens (phosphatase and tensin homolog, EP300-interacting inhibitor of differentiation 3 [EID3], EH domain-containing protein 1, galactoside-binding soluble 9, and BRCA1-associated protein). Further analysis using the AlphaLISA (R) immunoassay to compare serum antibody levels revealed that antibody levels against the EID3 antigen was significantly higher in the patient group than in the healthy donor group (n = 25, both groups). In addition, higher serum anti-EID3 antibody levels in NF-pNET patients correlated with shorter disease-free survival. The AUC calculated by ROC analysis was 0.784 with moderate diagnostic accuracy. In conclusion, serum anti-EID3 antibody levels may be useful as a tumor marker for prediction of tumor recurrence in NF-pNETs. |
| Rights: | http://creativecommons.org/licenses/by/3.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/68612 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
